Antimicrobial film supplier POSTsilver said on Thursday that it will launch its silver ion antibacterial film proven to kill 99.9% of germs and viruses including COVID-19 in Canada under an exclusive distribution agreement with Quebec-based company A2Z Wholesale Inc.
The company stated the POSTsilver is a transparent smart material created to protect high touch surfaces from retransmission of bacteria and viruses including COVID-19. It easily adheres to a wide array of surfaces in highly trafficked areas including elevator buttons, door handles, grocery carts, desks, ATM machines, rideshare vehicles surfaces, restaurant counters, and more.
In addition, the POSTsilver achieves its antimicrobial properties from the positive-charged silver ions and the FDA certified antibacterial agent NANOX. This proprietary technology is set in transparent vinyl sheets, which can last up to five years after installation.
According to the New England Journal of Medicine, the scientists at the National Institute of Allergy and Infectious Diseases found that COVID-19 was detectable for up to 72 hours on plastic and stainless steel, which makes engineering new solutions in addition to robust cleaning regiments ever more vital to health and safety.
Concurrently, the tests conducted by the Société Générale de Surveillance (SGS) laboratories demonstrated that POSTsilver reduces E. coli and Klebsiella pneumoniae by greater than 99.9% when tested for just one hour. Tests conducted for 24 hours demonstrated a reduction of greater than 99.9% of Staphylococcus and Salmonella.
CSL's ANDEMBRY receives European approval to prevent attacks of hereditary angioedema
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
European Commission approves Palforzia for toddlers with peanut allergy
Eli Lilly and Co receives approval from FDA for Zepbound
CSL gains EMA backing for Garadacimab as HAE prophylactic treatment
Merck initiates Phase 3 trial for LAGEVRIO (molnupiravir)
Allergy Therapeutics reports positive data from VLP Peanut PROTECT trial
CBC Group acquires UCB's mature neurology and allergy business in China
Allergy Therapeutics begins Phase III trial for grass allergy treatment in children